Peptides and Insulin Resistance: Metabolic Sensitivity Research

By the NorthPeptide Research Team  |  February 9, 2026

What Is Insulin Resistance?

Insulin resistance occurs when cells in the muscle, fat, and liver fail to respond normally to insulin — the hormone that signals cells to absorb glucose from the blood. The pancreas initially compensates by producing more insulin, but eventually cannot keep up, leading to elevated blood glucose and downstream metabolic dysfunction.

Insulin resistance is the central defect in Type 2 diabetes, and a major driver of cardiovascular disease, NAFLD, PCOS, and even some forms of cognitive decline. Understanding and reversing insulin resistance at the cellular level is one of the most important goals in metabolic research.

MOTS-c: AMPK Activation and Mitochondrial Metabolism

MOTS-c (Mitochondrial Open reading frame of the twelve S rRNA-c) is a 16-amino acid peptide encoded by mitochondrial DNA. It was identified in 2015 by researchers at USC and has attracted significant attention for its role in metabolic regulation.

In animal studies, MOTS-c administration improved insulin sensitivity in multiple models — including high-fat diet-fed mice, aged mice, and ovariectomised mice (a model of PCOS/menopause-related metabolic changes). The mechanism involves AMPK (AMP-activated protein kinase) activation in skeletal muscle, which promotes glucose uptake independently of insulin signalling. This is potentially significant because it suggests MOTS-c may be able to improve cellular glucose utilisation even in the presence of insulin resistance.

MOTS-c has also been shown to decline with age in humans — leading researchers to explore whether this decline contributes to age-associated insulin resistance and whether supplementation could reverse this effect.

NAD+ and Insulin Sensitivity

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to energy metabolism, DNA repair, and cellular signalling. Its levels decline with age and are reduced in states of metabolic disease. Research has shown a close relationship between NAD+ status and insulin sensitivity — specifically through its role in activating sirtuins (SIRT1-SIRT7), which regulate mitochondrial function, fatty acid oxidation, and gluconeogenesis.

Animal studies using NAD+ precursors (NMN, NR) showed improvements in insulin sensitivity, reduced liver fat, and improved glucose tolerance. SIRT1 activation in particular appears to improve insulin receptor signalling and reduce hepatic glucose production. While NAD+ as a standalone injectable compound is also being studied, most human research has focused on orally administered precursors.

GLP-1 Agonists: Indirect Insulin Sensitisation

GLP-1 receptor agonists like semaglutide improve insulin sensitivity primarily indirectly — through weight loss (reduced adipose tissue mass decreases inflammatory cytokines that impair insulin signalling), improved hepatic fat content, and reduced fasting free fatty acids. They also have direct effects on beta cell insulin secretion and glucagon suppression. In head-to-head comparisons, semaglutide has shown greater improvements in insulin sensitivity markers than some oral agents, partly attributable to its weight-loss effects.

The Mitochondrial Connection

A unifying thread in insulin resistance research is mitochondrial dysfunction. Impaired mitochondrial oxidative capacity in skeletal muscle leads to lipid accumulation inside muscle cells (intramyocellular lipid), which interferes with insulin signalling. Both MOTS-c and NAD+ work at the mitochondrial level to improve oxidative capacity and cellular energy homeostasis — which may explain their effects on insulin sensitivity. This mitochondrial-targeting approach is distinct from and potentially complementary to receptor-level approaches like GLP-1 agonism.

Adiponectin and Insulin Sensitisation

Adiponectin is an adipokine secreted by fat cells that has insulin-sensitising properties. It is paradoxically low in obesity despite being produced by fat tissue. Some peptide-related interventions that reduce adipose tissue mass (GLP-1 agonists, MOTS-c in the context of weight change) also tend to improve adiponectin levels — potentially creating a positive feedback loop where reduced fat mass → higher adiponectin → better insulin sensitivity.

References